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Abstract The question of when to start combination
antiretroviral therapy for treatment-naïve patients has
always been controversial. This is particularly true in the
current era, with major guidelines recommending very
different treatment strategies. Despite a lack of clarity
regarding the optimal time to begin therapy, there has been
a recent shift toward earlier initiation. This more aggressive
approach is driven by several observations. First, effective
viral suppression with therapy can prevent non-AIDS-
related morbidity and mortality. Second, therapy can
prevent irreversible harm to the human immune system.
Third, therapy may prevent transmission of HIV to others,
and thus have a potential public health benefit. For patients
who are motivated and willing to initiate early treatment,
the collective benefits of early therapy may outweigh the
well-documented risks of antiretroviral medications.
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Introduction
Since the introduction of zidovudine in 1987, the question
of when antiretroviral therapy for HIV should be initiated
has been often debated but never fully elucidated. Due to
the absence of a definitive and timely study, the decision of
“when to start” has often been based on expert interpreta-
tion of observational cohort data, HIV pathogenesis studies,
and the safety and efficacy of available therapeutic options
[1]. This review summarizes some of this historical context,
and then discusses the rationale for the current shift in
recommendations away from a conservative approach based
on delaying antiretroviral initiation as long as possible to a
muchmoreaggressiveapproachinwhichveryearlytherapyis
recommended or considered for nearly all patients. Critical
studies still in progress will also be reviewed, as will research
on the possible public health benefits of an aggressive “test
and treat” approach to therapy.
The Historical Perspective
After the introduction of zidovudine monotherapy as a
potentially effective agent, the question of “when to start”
this poorly tolerated drug became a dominant clinical
question. Several early studies attempted to address this
question. AIDS Clinical Trials Group 019 suggested that
over the short term, the use of zidovudine monotherapy in
asymptomatic patients was associated with measurable
clinical benefit [2], an observation that led to a general
recommendation that this drug be used early in the disease
process. This benefit, however, did not prove to be durable
[3], and a subsequent randomized trial of very early
zidovudine (CD4>500 cells/μL) compared to deferred
therapy (CD4<500 cells/μL) revealed no benefit for the
earlier use of this drug [4]. Therapeutic pessimism became
a dominant theme throughout the “when to start” debate.
This pessimism lifted with the advent of combination
antiretroviral therapy in 1996. The dramatic effects of three-
drug therapy in clinical trials, coupled with emerging insights
regarding viral dynamics and HIV evolution, renewed interest
in the concept that therapy should be initiated very early. Much
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hard”paradigm [5] and was reflected in the US Department of
Health and Human Services (DHHS) HIV treatment guide-
lines between 1998 and 2000, which recommended that most
patients be offered therapy, including those with asymptomatic
disease and a CD4 cell count above 500 cells/μL[ 6, 7].
After this period of expanding antiretroviral drug use,
concerns began to mount about the pill burden and
toxicities of antiretroviral regimens, and about the high
risk of developing drug-resistant HIV. This new awareness
of the limitations of therapy forced clinicians and expert
panels to question whether potential benefits of therapy
outweighed the potential risks at higher CD4 cell counts.
This, in turn, led to a sense among patients and clinicians
that medications should be delayed as long as possible.
Several cohort studies during this era indicated that a higher
pre-treatment CD4 was a strong predictor of good outcomes
during therapy, with consistent and clear benefits occurring
if therapy was initiated before the CD4 declined to below
200 cells/μL, but additional benefit was also apparent when
therapy was initiated at a CD4 of 200 to 350 cells/μL[ 8–10].
The 2001 version of the DHHS guidelines was according-
ly modified such that therapy was strongly recommended
for those with a CD4 below 200 cells/μL, and generally
recommended for those with a CD4 count of 200 to 350
cells/μL, although with certain caveats. Therapy in
patients with higher CD4 cell counts was generally not
recommended [11].
In recent years, the rationale for delaying antiretroviral
therapy has become less compelling. Co-formulation of
antiretroviral drugs has greatly improved, lowering the
average pill burden for patients, and allowing for an
antiretroviral regimen consisting of a single daily tablet
(tenofovir/emtricitabine/efavirenz). Side effect and toxicity
profiles have also improved. Several new potent and well-
tolerated options are now available, making it more likely
that all patients can be offered an effective regimen with
minimal side effects (and also making it more likely that
second-line and third-line options will be available if the
primary regimen fails to durably suppress viral replication).
Finally, and perhaps most importantly, evidence from a
randomized controlled trial (the Strategies for Management
of Antiretroviral Therapy, or SMART study) raised the
concernthatearlyuntreatedHIVinfectionmightbeassociated
with an increased risk of a number of important non-AIDS
conditions, including cardiovascular, liver, and kidney dis-
ease, as well as non-AIDS malignancies [12￿￿, 13￿￿]. Rather
than simply preventing classical AIDS-related opportunistic
conditions and deaths, many clinicians have come to believe
that antiretroviral therapy is also key to maintaining general
health. Several recent cohort studies (described below) have
provided some support for this far more aggressive approach
to therapy.
Observational Studies
Observational cohort studies have played a critical role in
the ongoing debate about the optimal time for the initiation
of antiretroviral therapy. Findings from cohort studies
played a particularly important role in showing mortality
benefits for antiretroviral initiation below a CD4 count of
350 cells/μL[ 8, 10, 14, 15]. The most clinically relevant
question now is to determine whether antiretroviral therapy
should be deferred until the CD4 count reaches 350 cells/μL,
or whether therapy should be started earlier. Here, again,
cohort studies continue to yield valuable although non-
definitive and often inconsistent insights.
A key study addressing the question of starting therapy
at a higher CD4 threshold was a 2009 analysis of patients in
NA-ACCORD, a large “cohort of cohorts” that merged
clinical data from 22 observational studies in the United
States and Canada. Kitahata et al. [16￿￿] identified treatment-
naive patients with CD4 counts in one of two strata: 350 to
500 cells/μL and more than 500 cells/μL. Patients who
entered the cohort with a CD4 cell count in these ranges and
who started therapy within the next 6 months were compared
to patients who did not initiate therapy and allowed their
CD4 cell counts to fall to below a predefined threshold.
Using inverse probability of treatment weighting methodol-
ogy, the authors performed two complementary analyses.
The first analysis concluded that deferral of therapy until a
CD4 cell count below 350 cells/μL was associated with a
69% increase in the relative risk of mortality as compared to
initiation of therapy between 350 and 500 cells/μL( a d j u s t e d
risk ratio: 1.69; 95% CI=1.26–2.26) [16￿￿]. These data were
generally consistent with other cohorts and post hoc analysis
of the SMART study (described below), and hence were not
particularly controversial. The second analysis showed that
deferral of therapy until the CD4 count was below 500 cells/
μL, as compared to initiation at a CD4 greater than 500 cells/
μL, was associated with a 94% increase in the relative risk
for death (adjusted risk ratio: 1.94; 95% CI=1.37–2.79). It is
important to stress that although the risk appeared to be
large, the number of events was small (even in the deferral
group), making the absolute level of clinical benefit
associated with early therapy unclear. Despite these con-
cerns, these data provided some evidence that very early
therapy may be beneficial, and provided clear evidence that
it was at least not harmful.
The NA-ACCORD study’s striking findings generated
some methodological criticisms, most of which were
centered around the possibility that the decision to initiate
therapy early in clinical practice was confounded by factors
that also influence mortality (the “healthy lifestyle bias”)
[17]. The authors addressed this possibility by simulating
how their results would change if a confounder with a very
strong association with both the exposure and outcome of
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slightly attenuated, and remained significantly in favor of
earlier antiretroviral therapy. Additional concerns about this
analysis included its complex sample selection scheme,
which excluded a large number of NA-ACCORD patients.
This may have rendered the study less generalizable to all
antiretroviral-naive patients, as it appeared to handle long-
term non-progressors (patients for whom the benefits of
early therapy are far less certain) differently in the two
comparison groups [18]. The results, however, did not
change appreciably when this censoring was handled non-
differentially, further supporting the central findings.
Another very influential 2009 cohort study, performed by
the Antiretroviral Therapy Cohort Collaboration (ART-CC),
examined 24,444 patients from 15 cohorts (most in Europe)
who initiated antiretroviral therapy at CD4 counts less than
550 cells/μL and compared mortality rates for different CD4
counts at treatment initiation [19￿￿]. One methodologic
concern with the ART-CC data was that it only included
data from the time antiretroviral therapy was initiated, and
thus did not have data regarding morbidity and mortality
during the pre-therapy untreated phase. This resulted in a
potential lead-time bias in which untreated patients who
developed an AIDS-defining event or who died before the
initiation of therapy could not be included in the analysis. To
address this concern [20], the authors analyzed event rates on
21,247 patients who received care between 1989 and 1995,
when combination antiretroviral therapy was not available.
They then used multiple imputation to allow these events to
represent those that might have occurred in the patients of
interest (individuals who started combination antiretroviral
drugs from 1996 onward), and allowed these events to
contribute to the calculated mortality rates. The final analysis
found that deferral of antiretroviral therapy until a CD4 count
of 251 to350cells/μL,comparedtoinitiatingtherapywhenat
a CD4 count of 351 to 450 cells/μL, was associated with an
adjusted 28% increase in the rate of death or AIDS (adjusted
hazard ratio for AIDS or death: 1.28; 95% CI=1.04–1.57)
[19￿￿]. The harm associated with deferring therapy was less
clear at CD4 counts more than 350 cells/μL. In contrast with
the NA-ACCORD analysis, the ART-CC analysis found no
clear risk in deferring therapy in patients with CD4 counts in
the higher ranges. For example, deferral of therapy until a
CD4 count of 351 to 450 cells/μL was not associated with
harm compared to initiation of therapy at a CD4 count of
451 to 550 cells/μL (adjusted hazard ratio for AIDS or death:
0.99; 95% CI=0.76–1.29). Similarly, deferral of therapy
until a CD4 count of 301 to 400 cells/μL, compared to
initiation of therapy at a CD4 count of 401 to 500 cells/μL,
was also not associated with harm (adjusted hazard ratio=
1.09; 95% CI=0.85–1.38). The authors conclude that a CD4
threshold of 350 cells/μL may be the optimal (or at least
minimal) threshold for initiating antiretroviral therapy.
As was the case with the NA-ACCORD study, this study
generated several methodologic criticisms. Chief among
these was that the imputed event and death rates from the
era before combination therapy became widely available
may have been different than in the modern treatment era
[21]. The authors acknowledged that these event rates were
potentially misrepresentative, but additional analyses show
that this was unlikely to have altered the fundamental
results [19￿￿]. Perhaps more importantly, non-AIDS-related
events, such as cardiovascular disease, renal disease, and
liver failure, were not included among the outcomes
analyzed. Given that the benefits of earlier antiretroviral
initiation may specifically involve these diseases, their
exclusion may at least partially explain why the study did
not show a clinical benefit when antiretroviral therapy was
started at CD4 counts above 350 cells/μL.
Randomized Controlled Clinical Trials
Most of the current recommendations on when to start
antiretroviral therapy are based primarily on observational
studies and HIV pathogenesis. Making clinical recommen-
dations based on such types of studies is problematic, a fact
well illustrated by the confusion regarding the use of
estrogen in postmenopausal women. Randomized clinical
trials are the gold standard methodology for generating
evidence to guide therapeutic strategies, and several have
provided clear support for the use of early therapy in
patients with lower CD4 cell counts [22, 23] and in HIV-
infected infants [24]. These studies, however, inform
different clinical questions than the current debate, which
focuses on asymptomatic adults with CD4 counts above
350 cells/μL.
Although not a classic “when to start” randomized
clinical trial, the SMART study has proven to be the most
important study in the modern era in terms of its impact on
when and how therapy is used. This study, which began in
2002 and was reported in 2006 [12￿￿], randomized more
than 5,000 patients to a continuous “viral suppression” arm,
in which antiretroviral therapy was started and continued
without regard to the CD4 count, versus a “drug conserva-
tion” arm, in which therapy was initiated if the CD4 count
declined below 250 cells/μL but halted if the CD4 count
rose above 350 cells/μL. The hazard ratio for opportunistic
disease or all-cause death for patients in the treatment
interruption arm was 2.6 (95% CI=1.9–3.7) [12￿￿]. When
investigators examined causes of death in the trial, they
found many patients had suffered from non-AIDS-related
morbidity and mortality, including cardiovascular, hepatic,
and renal disease. Indeed, the hazard ratio for these non-
AIDS-defining illnesses was 1.8 (95% CI=1.2–2.9), show-
ing that patients who discontinued antiretroviral therapy
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excess morbidity and mortality, chiefly manifest as cardio-
vascular, hepatic, and renal disease (though many suffered
traditional AIDS-related opportunistic diseases and death).
A subset of the SMART study reported data on 477
participants (9% of the original randomized trial) who atstudy
entry were either antiretroviral therapy naïve or who had been
untreated for at least 6 months [13￿￿]. In essence, this
substudy functioned like a randomized controlled trial of
antiretroviral initiation at CD4 counts more than 350 cells/μL
compared to deferral of therapy until CD4 counts were below
250 cells/μL. Subjects in the deferral arm fared poorly: the
hazard ratio for opportunistic disease or all-cause death was
3.47 (95% CI=1.26–9.56). Moreover, the hazard ratio for
serious non-AIDS events (defined as cardiovascular, hepatic,
andrenaldisease,alongwithnon-AIDS-relatedmalignancies)
was 7.02 (95% CI=1.57–31.38). Comparable trends were
observed when the analysis was limited to those who were
treatment naïve at study entry.
In the developing world, clinical practice has been most
strongly influenced by the World Health Organization
(WHO) treatment guidelines, which until recently recom-
mended initiating antiretroviral therapy at a target CD4
threshold of 200 cells/μL[ 25]. In 2009, the CIPRA-HT001
study was the first to investigate potential benefits of a
higher CD4 threshold for therapy in a developing world
setting where routine clinical practice is to initiate therapy
at a CD4 count of 200 cells/μL. Beginning in 2005,
investigators randomized 816 patients in Haiti with CD4
counts of 200 to 350 cells/μL to immediate antiretroviral
therapy versus deferral of therapy until either a CD4 less
than 200 cells/μL or an AIDS-defining diagnosis [26￿￿]. In
May 2009, a data safety monitoring board halted the trial
because the immediate treatment arm had markedly lower
mortality than the deferred treatment arm (six deaths vs 23
deaths, respectively). In addition, the study also showed
that incident tuberculosis was markedly reduced in the
immediate treatment arm (18 cases vs 36 cases). This study
played a central role in the November 2009 update to the
WHO treatment guidelines, which now recommend anti-
retroviral therapy for all persons with CD4 counts less than
350 cells/μL[ 27￿￿].
The Role of Antiretroviral Drugs in Reducing
Non-AIDS-Related Morbidity and Mortality
Despite tremendous reductions in AIDS-related deaths and
opportunistic disease in the combination antiretroviral era,
HIV-infected persons still suffer excess mortality compared
to the general population [28￿￿, 29–32]. Many studies have
shown that much of this excess mortality is attributable to
cardiovascular disease, non-AIDS-associated cancers, liver
disease,andkidneydisease[30, 33–35]. The increased risk of
these non-AIDS events is likely multifactorial in nature, and
includes an excess of traditional risk factors in HIV-positive
compared to HIV-negative persons, direct antiretroviral
treatment toxicities, and HIV-associated immunologic abnor-
malities that persist during treatment [33, 34]. Regardless of
the mechanisms, it is reasonable to assume that HIV-
associated morbidity and mortality in the future will likely
increasingly focus on the prevention and management of the
non-AIDS conditions.
The treatment-associated reductions in non-AIDS-
related conditions drove, in large part, the mortality
benefits observed in patients with CD4 counts more than
350 cells/μLi nt h eS M A R Ts t u d y[ 12￿￿], as well as in
patients with CD4 more than 500 cells/μL in the NA-
ACCORD analysis [16￿￿]. The discovery that treatment
can prevent these non-AIDS events is also supported by
robust analyses linking the on-therapy (or proximal) CD4
cell count with the short-term risk of developing a non-
AIDS event [34, 36–38]. Since lower on-therapy CD4 cell
counts predict an increased risk of non-AIDS events, it is
reasonable to assume that any intervention that prevents
the loss of immune function may be associated with
clinical benefit. Given the current inability to restore
immune function with immune-based therapeutics [39],
and given that HIV-associated immunodeficiency may be
irreversible in some patients [40, 41], the most effective
approach to preventing disease in HIV-positive persons
may be to initiate antiretroviral therapy before the onset of
any measurable immunodeficiency. Theoretically, this
would be as early as possible, perhaps even during
primary infection. It should be emphasized, however, that
the detrimental effects associated with lower on-therapy
CD4+ T-cell counts are only apparent in patients with CD4
cell counts well below 500 cells/μL.
HIV Pathogenesis and the Role of Inflammation
in Disease Outcomes
It is now well accepted that HIV-mediated increases in T-cell
activation have a central role in the pathogenesis of untreated
HIVinfection [42, 43]. T-cell activation also predicts a higher
risk of AIDS and death in late-stage disease [44]. Despite
these findings, the role of systemic inflammation in untreated
disease has previously received limited attention among
clinicians, who were understandably more focused on
achieving control of HIV replication. Now that we are in
an era in which nearly all motivated patients with access to
care can achieve durable and perhaps indefinite control of
HIV replication, more attention is turning to the potential
harms, both temporary and permanent, of HIV-associated
inflammatory states.
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play a central role in the pathogenesis of a number of non-
AIDS-related conditions not been previously linked to
immunodeficiency [45￿￿, 46]. Among the participants in
the SMART study (which compared continuous therapy vs
intermittent therapy), periods of untreated HIV infection
were associated with higher levels of biomarkers of
systemic inflammation and hypercoagulability [45￿￿]. The
levels of these biomarkers were associated with the overall
risk of mortality (importantly, this increased risk was
independent of both CD4 cell count and plasma HIV-1
RNA levels). A number of other studies have implicated
HIV-associated inflammation with premature onset of
cardiovascular disease, kidney dysfunction, liver failure,
neurocognitive decline, and osteopenia/osteoporosis [34].
Combination antiretroviral therapy lowers HIV-associated
immune activation over short time periods, but often does not
lower it to the level seen in HIV-negative persons [47]. That
this persistent inflammation is not abrogated by therapy is
particularly evident among patients who do not initiate
therapy until more advanced stages of HIV (CD4 counts<
350–500 cells/μL) [48]. These data collectively suggest but
do not definitively prove that persistent inflammation during
therapy is harmful, and that one way to prevent this process
may be to initiate therapy earlier in the disease process,
perhaps even before measurable immunodeficiency is readily
apparent. It is hoped that ongoing randomized studies of
“when to start” may provide a platform for exploring the role
of early therapy inpreventing irreversibleimmunologic harm.
Universal HIV Testing and Immediate Treatment:
The “Test and Treat” Strategy
Among untreated persons, the plasma HIV RNA level is a
strong and consistent predictor of a person’s ability to
transmit HIV to a partner. Although not formally proven, it
is highly likely that effective antiretroviral therapy dramat-
ically reduces the ability of an infected person to transmit
HIV to others. These observations and theoretical consid-
erations have led to an intriguing question: why not test as
many people as possible and then offer lifelong treatment to
those who are HIV positive? This so-called “test and treat”
approach has been advocated by others [49, 50] and has
been recently proposed in a widely publicized mathematical
model. This study, modeled on South African data and
reflective of a high-prevalence setting, showed that universal
annual voluntary HIV testing and immediate post-diagnosis
initiation of antiretroviral therapy in all persons older than
15 years could reduce the transmission of HIV and begin to
drive the HIV epidemic toward extinction [51￿￿]. Further-
more, the model indicates that an initial increase in cost (due
to an increasing number of patients requiring therapy) would
be followed by a subsequent further decrease in cost (due to
decreased incident cases) as more infections are prevented.
These potential public health considerations are increasingly
being used to support early therapy and were cited as
important by the DHHS Panel when their recommendations
shifted dramatically to earlier therapy (see below).
Major Revisions to Clinical Practice Guidelines
in 2008–2009
In 2008/09, several HIV treatment guidelines were revised
in favor of earlier initiation of antiretroviral therapy at
higher CD4 cell counts (Table 1). In December 2009, the
DHHS recommended therapy for all patients with CD4 cell
counts in the 350 to 500 cells/μL range, although the group
was divided as to whether this was a “strong” or
“moderate” recommendation. The DHHS panel was also
generally supportive of therapy in patients with CD4 cell
counts more than 500 cells/μL, with 50% recommending
therapy and 50% arguing that therapy should be optional (it is
of interest that the active deferral of therapy was not
recommended) [52￿￿]. The European AIDS Clinical Society
in November 2009 recommended treatment at a CD4 less
than 350 cells/uL, and consideration of treatment at CD4
counts more than 350 cells/μL if one or more comorbidity is
present [53]. The International AIDS Society USA and
British HIV Association 2008 guidelines are similar, recom-
mending therapy at a CD4 less than 350 cells/μLa n d
consideration of therapy at higher CD4 counts [54, 55]. In
November 2009, the WHO raised its recommended CD4
threshold for treatment to 350 cells/μL, a shift that will
undoubtedly have profound policy consequences throughout
the developing world [27￿￿]. They recommended deferral of
therapy for all patients with CD4 more than 350 cells/μL.
Key Clinical Studies Still in Progress
Two clinical trials are currently in progress, the results of
which are eagerly anticipated by the HIV community.
START (Strategic Timing of Antiretroviral Therapy) is a
clinical trial enrolling patients with CD4 counts more than
500 cells/μL and randomizing them to either immediate
therapy or deferral of therapy until the CD4 count is less
than 350 cells/μL. It will examine both AIDS-related and
non-AIDS-related events and deaths. HIV Prevention Trials
Network (HPTN) 052 is a clinical trial examining strategies
for preventing transmission of HIV in the developing
world. It is enrolling serodiscordant couples in which the
HIV-positive patient has a CD4 count of 350 to 550 cells/μL,
and randomizing these HIV-positive index patients to either
immediate therapy or deferral of therapy until a CD4 less than
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Curr HIV/AIDS Rep (2010) 7:60–68 65250 cells/μL. While the primary outcome isHIV transmission
to the HIV-negative partner, a secondary outcome will be the
clinical course of the index patients starting therapy at
different CD4 counts. Building on the CIPRA-HT001 study,
HPTN 052 will likely provide valuable insights into the
benefits and risks of initiating antiretroviral therapy at higher
CD4 counts in a developing-world setting.
Conclusions
Although the debate regarding when to start antiretroviral
therapy has been present for over two decades, consensus
on this question has been hard to achieve. This lack of
clarity continues in the current era, with major guidelines
recommending very different treatment strategies. All
agree, however, that the pendulum has swung back in
favor of more aggressive approaches to therapy. The
philosophy of delaying potentially toxic medications as
long as possible has increasingly shifted toward a philos-
ophy of initiating therapy as soon as possible. The debate
now and in the future will likely focus on the role of
antiretroviral therapy in preventing versus causing non-
AIDS-related conditions. These include heart, bone, liver,
kidney, and neurocognitive disease, as well as non-AIDS
malignancies,allofwhichappeartobemorecommoninHIV-
positive persons compared to their age-matched uninfected
peers. The potential public health benefits of early therapy in
reducing HIV transmission are generating thoughtful discus-
sion contributing to this debate. Several clinical trials of
different therapeutic strategies that are still in progress
promise to shed valuable light in the coming years on the
critical question of when to start antiretroviral therapy.
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